Selank / Semax Blend
GABAergic Anxiolysis + BDNF Nootropic Synergy
Selank / Semax Blend — Dual-Pathway Anxiolytic-Nootropic Stack
Last reviewed: August 2026
The Selank / Semax Blend combines two of Russia's most studied neuropeptides into one vial. Selank is a synthetic version of a natural immune peptide (tuftsin) that works on the same anxiety-calming system as Xanax — but without the sedation, dependence, or withdrawal. Semax is derived from a fragment of the stress hormone ACTH and is an approved pharmaceutical in Russia, used clinically for stroke recovery and cognitive enhancement. Together they tackle two different problems at once: Selank quiets the anxiety that gets in the way of clear thinking, while Semax directly boosts the brain chemicals (BDNF) that support memory and learning.
Selank works on GABA receptors — the same system that benzodiazepines target — but through a mechanism that doesn't appear to cause tolerance or dependence. It also increases BDNF (a key brain growth factor) and modulates serotonin. Semax works differently: it activates melanocortin receptors (MC4R) in the brain, which triggers a cascade that increases BDNF and NGF (nerve growth factor), supporting neuronal health and synaptic plasticity. The combination is designed so each compound handles what the other doesn't: Selank handles the anxiety/stress axis, Semax handles the cognitive performance axis.
Anxiety and cognitive performance are deeply intertwined — chronic stress and anxiety impair working memory, executive function, and learning through well-documented neurochemical mechanisms. Most interventions address one or the other. A combination that simultaneously reduces anxiety-driven cognitive interference (Selank) while directly amplifying the neurochemical machinery of cognition (Semax) represents a more complete approach to cognitive optimization research. Both compounds have real clinical histories in Russia, giving researchers a meaningful evidence base to build on.
This is one of the most mechanistically well-justified blends in the research peptide space. Both compounds have substantial peer-reviewed literature and real clinical use histories. The combination logic is sound: complementary, non-overlapping pathways with additive BDNF effects. The main research gap is dedicated combination studies. Research-only compound — not approved for human use.
What is Selank / Semax Blend?
The Selank / Semax Blend combines two of the most extensively studied Russian neuropeptides into a single research formulation. Selank (a synthetic heptapeptide derived from the endogenous immune peptide tuftsin) provides GABAergic anxiolysis and immune modulation, while Semax (an ACTH(4-7) Pro-Gly-Pro analog) drives BDNF upregulation and neuroprotective signaling. Together they target complementary but non-overlapping pathways: Selank quiets the stress-anxiety axis while Semax amplifies cognitive performance and neuroplasticity — a dual-mechanism approach that neither compound achieves alone.
- Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from the endogenous immune peptide tuftsin, with a Pro-Gly-Pro C-terminal extension that extends half-life from ~1 min to ~30 min and completed Phase III clinical trials in Russia for anxiety.
- Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH(4-7) analog registered as a pharmaceutical in Russia since 1994, used clinically for stroke recovery and cognitive impairment — one of the most clinically validated peptides in this catalog.
- Selank's primary mechanism is GABA-A receptor positive modulation (anxiolytic, non-sedating, non-habit-forming); Semax's primary mechanism is MC4R activation driving BDNF/NGF upregulation and TrkB/TrkA signaling (nootropic, neuroprotective).
- Both compounds independently upregulate BDNF through distinct mechanisms — Selank via GABAergic disinhibition, Semax via direct transcriptional activation — suggesting additive neuroplastic effects when combined.
- The blend targets the two primary neurochemical barriers to cognitive performance: anxiety-induced cognitive interference (Selank) and insufficient neuroplastic signaling capacity (Semax) — pathways that are complementary and non-competing.
Molecular Composition
Each vial contains a lyophilized co-formulation of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW 751.9 Da) and Semax (Met-Glu-His-Phe-Pro-Gly-Pro, MW 813.9 Da) at a combined 30mg total peptide content. Selank is a synthetic heptapeptide analog of the endogenous immunopeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro C-terminal sequence that increases metabolic stability from ~1 minute to approximately 30 minutes. Semax is derived from the ACTH(4-7) fragment (Met-Glu-His-Phe) with the same Pro-Gly-Pro stabilizing extension, originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both peptides are supplied as lyophilized powder requiring reconstitution with bacteriostatic or sterile water prior to research use.
How Does It Work?
Selank modulates GABA-A receptors to reduce anxiety without sedation; Semax activates MC4R to upregulate BDNF and drive neuroplasticity — two complementary pathways that together address both the anxiety and cognitive performance axes simultaneously.
The Selank / Semax Blend operates through two parallel and synergistic neurochemical pathways. Selank's primary mechanism involves positive allosteric modulation of GABA-A receptors, enhancing inhibitory neurotransmission in a manner mechanistically similar to benzodiazepines but without the receptor downregulation, sedation, or tolerance induction associated with classical GABA-A agonists. Selank also upregulates BDNF expression in the hippocampus and prefrontal cortex, modulates serotonin metabolism (increasing 5-HT turnover), and retains the immunomodulatory properties of its parent peptide tuftsin, which activates macrophages and NK cells via Fc receptor binding. Semax operates through a distinct but complementary mechanism: it binds to melanocortin receptors (MC4R) in the CNS and potently upregulates BDNF and NGF (Nerve Growth Factor) expression, activating downstream TrkB and TrkA receptor signaling cascades that promote neuronal survival, synaptic plasticity, and dendritic arborization. Semax also modulates the dopaminergic and serotonergic systems, enhancing catecholamine synthesis and release in prefrontal circuits. The synergy of this blend lies in the complementary resolution of the two primary barriers to optimal cognitive performance: Selank reduces the anxiety and stress-induced cognitive interference that impairs working memory and executive function, while Semax directly amplifies the neurochemical machinery underlying memory consolidation and cognitive processing speed. BDNF upregulation from both compounds is additive — Selank via GABAergic disinhibition of BDNF release and Semax via direct transcriptional activation — potentially producing greater neuroplastic effects than either compound alone.
Key Research Pathways
GABA-A Receptor Modulation (Selank)
Selank positively modulates GABA-A receptors, enhancing inhibitory neurotransmission and producing anxiolytic effects without the sedation, tolerance, or withdrawal associated with classical benzodiazepines. This mechanism quiets hyperactive stress circuits in the amygdala and prefrontal cortex.
BDNF / TrkB Signaling (Semax)
Semax potently upregulates BDNF (Brain-Derived Neurotrophic Factor) expression via MC4R activation, driving downstream TrkB receptor signaling that promotes neuronal survival, synaptic plasticity, long-term potentiation, and dendritic arborization — the molecular substrate of learning and memory.
Dual BDNF Upregulation (Synergy)
Both Selank (via GABAergic disinhibition of BDNF release) and Semax (via direct transcriptional activation) independently upregulate BDNF. When combined, this dual-pathway BDNF amplification may produce additive or synergistic neuroplastic effects exceeding either compound alone.
Serotonergic Modulation
Selank increases 5-HT (serotonin) turnover and modulates serotonin metabolism, contributing to mood stabilization and emotional regulation. Semax also influences serotonergic circuits, with both compounds showing complementary effects on the 5-HT system.
NMDA Receptor Glycine Site (Shared Mechanism)
Both Selank and Semax modulate the glycine co-agonist site of NMDA receptors in a strain-dependent manner, providing a shared mechanistic basis for their synergistic cognitive effects — particularly relevant in models of cognitive deficit and anxiety-induced cognitive impairment.
Tuftsin Immunomodulatory Pathway (Selank)
Selank retains the immunomodulatory properties of its parent peptide tuftsin, activating macrophages and NK cells via Fc receptor binding and normalizing IL-6 levels. This neuroimmune modulation may contribute to the compound's stress-resilience effects.
Key Findings from the Literature
- Selank completed Phase III clinical trials in Russia for generalized anxiety disorder and demonstrated anxiolytic efficacy comparable to benzodiazepines without sedation, dependence, or withdrawal (Zozulya et al., 2001)
- Semax is registered as a pharmaceutical drug in Russia (since 1994) and is used clinically for ischemic stroke recovery, cognitive impairment, and optic nerve disease — one of the most clinically validated peptides in this catalog
- Selank upregulates BDNF mRNA expression in the hippocampus by approximately 1.4-fold in rodent models, while Semax produces BDNF upregulation of 1.6-fold — suggesting additive neuroplastic effects when combined (Dolotov et al., 2006; Semenova et al., 2009)
- The NMDA receptor glycine site modulation shared by both Selank and Semax (Gudasheva et al., 2023) provides a mechanistic basis for their synergistic cognitive effects, particularly in models of cognitive deficit
- Selank's tuftsin-derived immunomodulatory activity (IL-6 normalization, NK cell activation) complements Semax's neuroprotective effects, potentially supporting neuroimmune homeostasis in stress models
- Both peptides share the Pro-Gly-Pro C-terminal stabilization sequence, suggesting they may be metabolized through similar enzymatic pathways, which may reduce competitive metabolism when co-administered
Important Research Context
Research References
Peer-reviewed literature supporting the research profile of Selank / Semax Blend
The following peer-reviewed studies form the primary evidence base for Selank / Semax Blend's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
- 1.
Semenova TP, et al. Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA. Eksperimental'naia i Klinicheskaia Farmakologiia. 2009.PMID: 19803361
Selank demonstrated anxiolytic and nootropic effects in rodent behavioral models, with BDNF upregulation in hippocampal tissue.
- 2.
Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006.PMID: 16996037
Semax upregulated BDNF mRNA and TrkB receptor expression in the hippocampus, providing the molecular basis for its cognitive-enhancing effects.
- 3.
Zozulya AA, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001.PMID: 11550013
Tuftsin-based peptides including Selank modulate anxiety through endogenous GABAergic and opioid systems without dependence liability.
Selank / Semax Blend
Blends Research
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
Use code HEALTH for 20% off
Fast FedEx shipping · Discreet packaging
Technical Specifications
| Selank Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 AA) |
| Semax Sequence | Met-Glu-His-Phe-Pro-Gly-Pro (7 AA) |
| Selank MW | 751.9 Da |
| Semax MW | 813.9 Da |
| Total Vial Content | 30mg lyophilized blend |
| Purity | ≥99% (third-party COA) |
| Form | Lyophilized powder |
| Storage | −20°C (lyophilized), 4°C (reconstituted) |
| Half-life (Selank) | ~30 min (in vivo, intranasal) |
| Half-life (Semax) | ~20 min (in vivo, intranasal) |
| Origin | Institute of Molecular Genetics, Russian Academy of Sciences |
Source Selank / Semax Blend at Purgo Labs
≥99% purity · Third-party COA · Use code HEALTH for 20% off
Other Compounds in This Guide
Supporting Research
Selank-Semax blend combines two Russian-approved neuropeptides. Individual constituent evidence exists (Russian trials, limited Western replication). No clinical trials have been conducted on this specific blend formulation.
References
- Semenova TP, et al.HUMAN — Selank constituent, Russian trialsBulletin of Experimental Biology and Medicine. 2010. PubMedSelank anxiolytic evidence from Russian clinical studies; limited independent Western replication.
Research Databases
Ready to Source Selank / Semax Blend?
Purgo Labs offers Selank / Semax Blend with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.